专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20120309832A1 Acetylcysteine Composition and Uses Thereof 有权
标题翻译：乙酰半胱氨酸组成及用途
公开(公告)号：US20120309832A1
公开(公告)日：2012-12-06
申请号：US13406175
申请日：2012-02-27
申请人： Leo Pavliv
发明人： Leo Pavliv
IPC分类号： A61K31/198 , A61P39/06
CPC分类号： A61K31/198 , A61J1/05 , A61K9/0019 , A61K9/08 , A61K31/195 , A61K31/197 , A61K47/02 , A61K47/26 , B65B7/00
摘要： This invention relates to novel acetylcysteine compositions in solution, comprising acetylcysteine and which are substantially free of metal chelating agents, such as EDTA. Further, this invention relates to methods of making and using the acetylcysteine compositions. The present compositions and methods are designed to improve patient tolerance and compliance, while at the same time maintaining the stability of the pharmaceutical formulation. The compositions and methods of this invention are useful in the treatment of acetaminophen overdose, acute liver failure, various cancers, methacrylonitrile poisoning, reperfusion injury during cardio bypass surgery, and radiocontrast-induced nephropathy, and can also be used as a mucolytic agent.
摘要翻译：本发明涉及溶液中的新型乙酰半胱氨酸组合物，其包含乙酰半胱氨酸，其基本上不含金属螯合剂，例如EDTA。此外，本发明涉及制备和使用乙酰半胱氨酸组合物的方法。本发明的组合物和方法旨在改善患者耐受性和依从性，同时保持药物制剂的稳定性。本发明的组合物和方法可用于治疗对乙酰氨基酚过量，急性肝衰竭，各种癌症，甲基丙烯腈中毒，心脏旁路手术期间的再灌注损伤和放射性对照诱导的肾病，并且还可用作粘液溶解剂。

2. 发明申请

US20100234465A1 Administration of Intravenous Ibuprofen 有权
标题翻译：静脉注射布洛芬
公开(公告)号：US20100234465A1
公开(公告)日：2010-09-16
申请号：US12722682
申请日：2010-03-12
申请人： Leo Pavliv
发明人： Leo Pavliv
IPC分类号： A61K31/19 , A61P29/00 , A61P41/00
CPC分类号： A61K9/0019 , A61K9/08 , A61K31/192 , A61K31/485 , A61K2300/00
摘要： An effective dose of intravenous ibuprofen administered every 6 hours in surgery patients is a safe and effective way to reduce both pain and the need for morphine. In preferred embodiments, the administration of intravenous ibuprofen starts with the onset of anesthesia.
摘要翻译：在手术患者中每6小时施用一次静脉注射布洛芬的有效剂量是减轻疼痛和吗啡需求的安全有效的方法。在优选的实施方案中，静脉注射布洛芬的施用开始于麻醉开始。

3. 发明授权

US06727286B2 Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid 有权
标题翻译： 2-（4-异丁基苯基）丙酸的药物组合物
公开(公告)号：US06727286B2
公开(公告)日：2004-04-27
申请号：US09985246
申请日：2001-11-02
申请人： Leo Pavliv
发明人： Leo Pavliv
IPC分类号： A61K31195
CPC分类号： A61K31/192 , A61K9/19 , A61K31/198 , A61K2300/00
摘要： The present invention provides a pharmaceutical composition comprising an aqueous solution of arginine and ibuprofen, wherein the molar ratio of arginine to ibuprofen is less than 1:1, as well as a method of making the same. The present invention also provides a method of treating a condition chosen from pain, inflammation, fever, and/or other conditions alleviated by ibuprofen comprising administering a pharmaceutical composition comprising an aqueous solution of arginine and ibuprofen, wherein the molar ratio of arginine to ibuprofen is less than 1:1.
摘要翻译：本发明提供了包含精氨酸和布洛芬的水溶液的药物组合物，其中精氨酸与布洛芬的摩尔比小于1:1，以及其制备方法。本发明还提供了治疗选自由布洛芬缓解的疼痛，炎症，发热和/或其他病症的病症的方法，其包括给药包含精氨酸和布洛芬的水溶液的药物组合物，其中精氨酸与布洛芬的摩尔比为小于1：1。

4. 发明授权

US08778907B2 Lactulose for bowel evacuation 有权
标题翻译：用于肠排空的乳果糖
公开(公告)号：US08778907B2
公开(公告)日：2014-07-15
申请号：US13284332
申请日：2011-10-28
申请人： Leo Pavliv , Bryan Voss
发明人： Leo Pavliv , Bryan Voss
IPC分类号： A61K31/70
CPC分类号： A61K31/7016 , A61K9/0095 , A61K31/375 , A61K33/00 , A61K33/14 , A61K45/06 , A61K2300/00
摘要： A method of treating an adult patient in need of bowel evacuation via the administration of one or more doses of a bowel evacuant consisting of a total of from about 180 g to about 220 g of lactulose in a dosing regimen suitable to achieve bowel evacuation prior to a diagnostic, therapeutic or surgical procedure is disclosed.
摘要翻译：一种治疗需要肠排空的成年患者的方法，所述成年患者通过施用一种或多种剂量的肠排空剂，所述剂量由总共约180g至约220g的乳果糖组成，其适于在适于在公开了诊断，治疗或外科手术。

5. 发明授权

US08735452B2 Treating patients with intravenous ibuprofen 有权
标题翻译：治疗静脉注射布洛芬的患者
公开(公告)号：US08735452B2
公开(公告)日：2014-05-27
申请号：US12699595
申请日：2010-02-03
申请人： Leo Pavliv , Amy Dix Rock
发明人： Leo Pavliv , Amy Dix Rock
IPC分类号： A01N37/10 , A61K31/19
CPC分类号： A61K9/0019 , A61K31/19 , A61K31/192 , A61K31/198
摘要： Methods of treating a patient in need thereof, comprising administering to the critically ill patient an intravenous pharmaceutical composition comprising ibuprofen in an amount effective to treat at least one condition in the patient chosen from pain, inflammation, and fever and to provide a clinically relevant effect on mean arterial pressure of the patients during the dosage interval comprising no increase or no statistically significant increase in mean arterial pressure.
摘要翻译：治疗有需要的患者的方法包括向危重患者施用含有有效治疗选自疼痛，炎症和发热的患者中的至少一种状况的布洛芬的静脉内药物组合物并提供临床相关效应在剂量间隔期间患者的平均动脉压不包括平均动脉压升高或无统计学显着性增加。

6. 发明授权

US08399445B2 Acetylcysteine composition and uses thereof 有权
公开(公告)号：US08399445B2
公开(公告)日：2013-03-19
申请号：US13406175
申请日：2012-02-27
申请人： Leo Pavliv
发明人： Leo Pavliv
IPC分类号： A61K31/33
CPC分类号： A61K31/198 , A61J1/05 , A61K9/0019 , A61K9/08 , A61K31/195 , A61K31/197 , A61K47/02 , A61K47/26 , B65B7/00
摘要： This invention relates to novel acetylcysteine compositions in solution, comprising acetylcysteine and which are substantially free of metal chelating agents, such as EDTA. Further, this invention relates to methods of making and using the acetylcysteine compositions. The present compositions and methods are designed to improve patient tolerance and compliance, while at the same time maintaining the stability of the pharmaceutical formulation. The compositions and methods of this invention are useful in the treatment of acetaminophen overdose, acute liver failure, various cancers, methacrylonitrile poisoning, reperfusion injury during cardio bypass surgery, and radiocontrast-induced nephropathy, and can also be used as a mucolytic agent.

7. 发明申请

US20120277181A1 LACTULOSE FOR BOWEL EVACUATION 有权
标题翻译：用于BOWEL EVACUATION的乳糖
公开(公告)号：US20120277181A1
公开(公告)日：2012-11-01
申请号：US13284332
申请日：2011-10-28
申请人： Leo PAVLIV , Bryan VOSS
发明人： Leo PAVLIV , Bryan VOSS
IPC分类号： A61K31/7016 , A61P1/10
CPC分类号： A61K31/7016 , A61K9/0095 , A61K31/375 , A61K33/00 , A61K33/14 , A61K45/06 , A61K2300/00
摘要： A method of treating an adult patient in need of bowel evacuation via the administration of one or more doses of a bowel evacuant consisting of a total of from about 180 g to about 220 g of lactulose in a dosing regimen suitable to achieve bowel evacuation prior to a diagnostic, therapeutic or surgical procedure is disclosed.
摘要翻译：一种治疗需要肠排空的成年患者的方法，所述成年患者通过施用一种或多种剂量的肠排空剂，所述剂量由总共约180g至约220g的乳果糖组成，其适于在适于在公开了诊断，治疗或外科手术。

8. 发明授权

US08148356B2 Acetylcysteine composition and uses therefor 有权
标题翻译：乙酰半胱氨酸组合物及其用途
公开(公告)号：US08148356B2
公开(公告)日：2012-04-03
申请号：US11209804
申请日：2005-08-24
申请人： Leo Pavliv
发明人： Leo Pavliv
IPC分类号： A61K31/33
CPC分类号： A61K31/198 , A61J1/05 , A61K9/0019 , A61K9/08 , A61K31/195 , A61K31/197 , A61K47/02 , A61K47/26 , B65B7/00
摘要： This invention relates to novel acetylcysteine compositions in solution, comprising acetylcysteine and which are substantially free of metal chelating agents, such as EDTA. Further, this invention relates to methods of making and using the acetylcysteine compositions. The present compositions and methods are designed to improve patient tolerance and compliance, while at the same time maintaining the stability of the pharmaceutical formulation. The compositions and methods of this invention are useful in the treatment of acetaminophen overdose, acute liver failure, various cancers, methacrylonitrile poisoning, reperfusion injury during cardio bypass surgery, and radiocontrast-induced nephropathy, and can also be used as a mucolytic agent.
摘要翻译：本发明涉及溶液中的新型乙酰半胱氨酸组合物，其包含乙酰半胱氨酸，其基本上不含金属螯合剂，例如EDTA。此外，本发明涉及制备和使用乙酰半胱氨酸组合物的方法。本发明的组合物和方法旨在改善患者耐受性和依从性，同时保持药物制剂的稳定性。本发明的组合物和方法可用于治疗对乙酰氨基酚过量，急性肝衰竭，各种癌症，甲基丙烯腈中毒，心脏旁路手术期间的再灌注损伤和放射性对照诱导的肾病，并且还可用作粘液溶解剂。

9. 发明申请

US20110028556A1 TREATING CRITICALLY ILL PATIENTS WITH INTRAVENOUS IBUPROFEN 审中-公开
标题翻译：用异常IBUPROFEN治疗严重的ILL患者
公开(公告)号：US20110028556A1
公开(公告)日：2011-02-03
申请号：US12570912
申请日：2009-09-30
申请人： Leo Pavliv , Amy D. Rock
发明人： Leo Pavliv , Amy D. Rock
IPC分类号： A61K31/192 , A61P25/00 , A61P29/00
CPC分类号： A61K31/192 , A61K9/0019
摘要： Methods of treating at least one condition chosen from pain, inflammation, and fever in a critically ill patient in need thereof, comprising administering to the critically ill patient an intravenous pharmaceutical composition comprising ibuprofen using a first dosage regimen, wherein the first dosage regimen produces a first pharmacokinetic profile in critically ill patients that is about equivalent to a second pharmacokinetic profile produced by administration of the intravenous pharmaceutical composition using a second dosage regimen of ibuprofen to non-critically ill patients, wherein the at least one condition of the critically ill patient is thereby treated.
摘要翻译：在有需要的危重病人中治疗选自疼痛，炎症和发烧的至少一种病症的方法，包括使用第一剂量方案向危重患者施用包含布洛芬的静脉内药物组合物，其中所述第一剂量方案产生危重症患者的第一药代动力学特征，其大致相当于使用静脉注射药物组合物使用布洛芬的第二剂量方案给予非危重患者的第二药代动力学特征，其中危重患者的至少一种状况是从而进行治疗。

10. 发明申请

US20100105605A1 FATTY ACID FORMULATIONS AND ORAL DELIVERY OF PROTEINS AND PEPTIDES, AND USES THEREOF 有权
标题翻译：脂肪酸制剂和口服递送蛋白质和肽，及其用途
公开(公告)号：US20100105605A1
公开(公告)日：2010-04-29
申请号：US12581953
申请日：2009-10-20
申请人： Balasingam Radhakrishnan , Diti Aggarwal , Michelle Ferro , Kenneth D. James , Navdeep B. Malkar , Mark A. Miller , Leo Pavliv , Karen Polowy , Monica Puskas , Nnochiri N. Ekwuribe
发明人： Balasingam Radhakrishnan , Diti Aggarwal , Michelle Ferro , Kenneth D. James , Navdeep B. Malkar , Mark A. Miller , Leo Pavliv , Karen Polowy , Monica Puskas , Nnochiri N. Ekwuribe
IPC分类号： A61K38/28 , A61P3/10
CPC分类号： C07K14/62 , A61K9/0095 , A61K9/2013 , A61K9/2018 , A61K33/30 , A61K38/00 , A61K38/28 , A61K45/06 , A61K47/60 , A61K47/69 , A61K2300/00
摘要： Fatty acid compositions for administration of of pharmaceutical agents, such as proteins and peptides, protein and peptide conjugates, and/or cation-polypeptide conjugate complexes. In particular, the invention provides a solid pharmaceutical composition formulated for oral administration by ingestion, having from about 0.1 to about 75% w/w fatty acid component, where the fatty acid component comprises saturated or unsaturated C4, C5, C6, C7, C8, C9, C10, C11, or C12 fatty acids and/or salts of such fatty acids; and a therapeutic agent. Further, the invention provides a liquid pharmaceutical composition formulated for oral administration by ingestion, comprising: from about 0.1 to about 10% w/v fatty acid component, where the fatty acid component comprises saturated or unsaturated C4, C5, C6, C7, C8, C9, C10, C11, or C12 fatty acids and/or salts of such fatty acids; and a therapeutic agent.
摘要翻译：用于施用药剂例如蛋白质和肽，蛋白质和肽缀合物和/或阳离子 - 多肽缀合物复合物的脂肪酸组合物。特别地，本发明提供了一种配制成通过摄取口服给药的固体药物组合物，其具有约0.1至约75％w / w脂肪酸组分，其中脂肪酸组分包含饱和或不饱和C4，C5，C6，C7，C8 ，C9，C10，C11或C12脂肪酸和/或这些脂肪酸的盐; 和治疗剂。此外，本发明提供配制成通过摄取口服给药的液体药物组合物，其包含：约0.1至约10％w / v脂肪酸组分，其中脂肪酸组分包含饱和或不饱和C4，C5，C6，C7，C8 ，C9，C10，C11或C12脂肪酸和/或这些脂肪酸的盐; 和治疗剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式